Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays dropped their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Trading Down 2.0 %

NASDAQ CLLS opened at $1.96 on Friday. The firm’s fifty day moving average price is $1.93 and its 200 day moving average price is $2.12. The company has a market capitalization of $108.94 million, a price-to-earnings ratio of -1.51 and a beta of 3.09. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. Cellectis has a 12 month low of $1.70 and a 12 month high of $3.77.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $18.05 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter in the previous year, the firm posted ($0.31) earnings per share. On average, sell-side analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CLLS. XTX Topco Ltd acquired a new position in shares of Cellectis during the second quarter valued at about $29,000. First Affirmative Financial Network acquired a new position in shares of Cellectis during the third quarter worth approximately $45,000. Principal Financial Group Inc. boosted its holdings in Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares during the last quarter. Finally, Long Focus Capital Management LLC grew its holdings in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.